ArticleScientific reports2026
Synthesis and biological evaluation of 6-hydroxychromone based thiosemicarbazones as potential antidiabetic and antioxidant agents.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A quarter-century journey into 4-chromone derivatives: synthesis, reactions, and pioneering applications thereof.RSC advances · 2026Review
- Novel Hybrid Scaffold of Pyrazole, Thiazole, and [1,2,3]triazole: Eco-Friendly Synthesis by DABCO, Anti-HIV-1 RT, and In Silico Studies.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new series of 6-hydroxychromone-based thiosemicarbazones 4(a-p) was synthesized and assessed for their antidiabetic (α-Glucosidase and α-Amylase inhibition) as well as antioxidant (2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2´-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)) activities. Among the synthesized compounds, compound 4k (IC50 = 1.18 ± 0.19 µg/mL) emerged as the promising α-Glucosidase inhibitor, significantly outperforming the reference drug Acarbose (IC50 = 7.33 ± 0.13 µg/mL). For α-Amylase inhibition, compound 4 g (IC50 = 13.61 ± 2.04 µg/mL) demonstrated excellent activity, compared to Acarbose (IC50 = 43.15 ± 5.22 µg/mL). In antioxidant assays, compound 4o (IC50 = 15.30 ± 1.70 µg/mL) exhibited the strongest DPPH radical scavenging effect, and compound 4 g (IC50 = 6.06 ± 0.15 µg/mL) showed the highest ABTS scavenging activity, surpassing the standard antioxidant Trolox (IC50 = 30.20 ± 5.14 & 18.19 ± 2.47 µg/mL, respectively). Remarkably, these derivatives showed greater efficacy compared to standard inhibitors, underscoring their promise as novel candidates for antidiabetic and antioxidant drug development. Molecular docking analysis demonstrated strong binding and critical interactions within the enzyme active sites. MD simulations confirmed the stability of 4k-α-Glucosidase and 4 g-α-Amylase, with RMSD values below 3.6 Å, low RMSF (< 2.8 Å) at the binding site, and sustained key interactions with Phe 158 and Tyr 151, respectively. The network pharmacology further supported the findings of molecular docking and simulation analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.